ALGN
stock Healthcare Medical Instruments & SuppliesOverall Mixed · 44%
- Fundamentals Fair
- Trajectory Slipping
- Leadership Normal
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 3 of 5 trend signals bullishRSI 42 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $161.71
- -2.99%
- Close
- $161.71
- -2.99%
- Current
- $161.71
- Prev close
- $166.69
- Today
- 952.52K
- 3-mo avg
- 1.14M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2983 days ago
- Next expected
- Jul 29in 8 days
Recent earnings dates
- Apr 29 83 days ago
- Feb 4 167 days ago
- Oct 29, 2025 265 days ago
- Jul 30, 2025 356 days ago
Past earnings dates come from ALGN’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), ALGN’s fundamentals read as fair overall.
At 27.2x, investors are paying up; a fair amount of future growth is already in the price.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 10.2% margin is solid, in the ordinary range for a profitable company.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 10.1% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 6.6% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 0.54, the company carries less in liabilities than in equity, a conservative balance sheet.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.36, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 0.9% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income fell 2.6% from the prior year; profit is shrinking.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $4.0B | $3.7B | $3.9B | $4.0B | $4.0B |
| Net income | $772.0M | $361.6M | $445.1M | $421.4M | $410.4M |
| Diluted EPS | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 |
| Dividend / share | — | — | — | — | — |
| Total assets | $5.9B | $5.9B | $6.1B | $6.2B | $6.2B |
| Total liabilities | $2.3B | $2.3B | $2.5B | $2.4B | $2.2B |
| Shareholder equity | $3.6B | $3.6B | $3.6B | $3.9B | $4.0B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $977.9M | $995.2M | $979.3M | $1.0B | $995.7M | $1.0B | $1.0B |
| Net income | $96.6M | $116.0M | $103.8M | $93.2M | $124.6M | $56.8M | $135.8M | $112.8M |
| Diluted EPS | $1.28 | $1.55 | $1.40 | $1.27 | $1.72 | $0.78 | $1.88 | $1.57 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 58d ago
- Hogan Joseph M President and CEO · Director
- Morici John EVP, CHIEF FINANCIAL OFFICER
- Coletti Julie Ann EVP, CHIEF LEGAL & REGULATORY
- Hockridge Stuart A EVP, GLOBAL HR
- Marree Jitse See Remarks
- Richardson Jaime Holte See Remarks
- Conroy Kevin T Director
- Dallas Kevin J Director
- Lacob Joseph Director
- Larkin C Raymond Jr Director
- Morrow George J Director
- Myong Anne Director
- Poul Mojdeh Director
- Saia Andrea Lynn Director
- Siegel Susan E Director
- Vitalone Britt J. Director
Officers and board are drawn from ALGN’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 28 +6.4% one-day move
- Apr 8 +6.0% one-day move
- Mar 27 −6.2% one-day move
- Feb 12 −6.9% one-day move
- Feb 6 +6.8% one-day move
- Feb 5 +8.9% one-day move
- Sep 23, 2025 New 6-month low (-38% off peak)
- Sep 18, 2025 Officer or director change reported in an 8-K
- Jul 31, 2025 New 6-month low (-43% off peak)
- Jul 31, 2025 −36.6% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report